文献速递外周动脉疾病

血运重建策略对BEST-CLI试验中临床失败、血流动力学失败及慢性肢体威胁性缺血症状的影响

The impact of revascularization strategy on clinical failure, hemodynamic failure, and chronic limb-threatening ischemia symptoms in the BEST-CLI Trial.
PubMed 文献 · J Vasc Surg · 2024-07-26

该研究为BEST-CLI试验的计划二次分析,按意向治疗比较血管内(ENDO)与旁路(OPEN)血运重建后临床失败、血流动力学失败及CLTI症状缓解率。在队列1(有合适SSGSV,N=1434)中,OPEN在临床失败、血流动力学失败及症状缓解时间上均显著优于ENDO;队列2(缺乏合适SSGSV,N=396)中OPEN的血流动力学失败率显著更低。多变量分析显示OPEN与两队列临床和血流动力学失败风险显著降低相关,队列1中初始症状缓解及预防复发CLTI的可能性显著更高。

要点

  • 队列1中OPEN较ENDO显著改善临床失败、血流动力学失败及症状缓解时间。
  • 队列2中OPEN较ENDO显著降低血流动力学失败率,临床失败及症状缓解无显著差异。
  • OPEN与两队列临床和血流动力学失败风险显著降低相关,队列1中症状缓解可能性显著更高。

核心结论

  • 与ENDO相比,初始采用OPEN外科旁路(尤其在有可用大隐静脉时)与更好的临床和血流动力学结局及CLTI症状缓解增强相关。

研究设计与样本

  • BEST-CLI试验的计划二次分析,按意向治疗分配进行时间-事件分析,并构建多变量分层Cox回归模型。
  • 队列1为有合适单段大隐静脉(SSGSV)者,N=1434;队列2为缺乏合适SSGSV者,N=396。

主要发现

  • 队列1中,临床失败时间(log-rank P < .001)、血流动力学失败时间(log-rank P < .001)及初始症状缓解时间(log-rank P = .009)均显著有利于OPEN。
  • 队列2中,血流动力学失败率显著有利于OPEN(log-rank P = .006),临床失败时间或初始症状缓解时间无显著差异。
  • 多变量分析显示,分配至OPEN与两队列临床和血流动力学失败风险显著降低相关,并与队列1中初始CLTI症状缓解可能性显著更高及预防复发CLTI相关,包括对关键基线协变量调整后。
  • 与临床失败独立相关的因素包括队列1中年龄>80岁及两队列中终末期肾病(ESRD);ESRD与队列1血流动力学失败相关。
  • 与初始症状缓解较慢相关的因素包括队列1中糖尿病及队列2中WIfI分期。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Sustained clinical and hemodynamic benefit after revascularization for chronic limb-threatening ischemia (CLTI) is needed to resolve symptoms and prevent limb loss. We sought to compare rates of clinical and hemodynamic failure as well as resolution of initial and prevention of recurrent CLTI after endovascular (ENDO) vs bypass (OPEN) revascularization in the Best-Endovascular-versus-best-Surgical-Therapy-in-patients-with-CLTI (BEST-CLI) trial. METHODS: As planned secondary analyses of the BEST-CLI trial, we examined the rates of (1) clinical failure (a composite of all-cause death, above-ankle amputation, major reintervention, and degradation of WIfI stage); (2) hemodynamic failure (a composite of above-ankle amputation, major and minor reintervention to maintain index limb patency, failure to an initial increase or a subsequent decrease in ankle brachial index of 0.15 or toe brachial index of 0.10, and radiographic evidence of treatment stenosis or occlusion); (3) time to resolution of presenting CLTI symptoms; and (4) incidence of recurrent CLTI. Time-to-event analyses were performed by intention-to-treat assignment in both trial cohorts (cohort 1: suitable single segment great saphenous vein [SSGSV], N = 1434; cohort 2: lacking suitable SSGSV, N = 396), and multivariate stratified Cox regression models were created. RESULTS: In cohort 1, there was a significant difference in time to clinical failure (log-rank P < .001), hemodynamic failure (log-rank P < .001), and resolution of presenting symptoms (log-rank P = .009) in favor of OPEN. In cohort 2, there was a significantly lower rate of hemodynamic failure (log-rank P = .006) favoring OPEN, and no significant difference in time to clinical failure or resolution of presenting symptoms. Multivariate analysis revealed that assignment to OPEN was associated with a significantly lower risk of clinical and hemodynamic failure in both cohorts and a significantly higher likelihood of resolving initial and preventing recurrent CLTI symptoms in cohort 1, including after adjustment for key baseline patient covariates (end-stage renal disease [ESRD], prior revascularization, smoking, diabetes, age >80 years, WIfI stage, tissue loss, and infrapopliteal disease). Factors independently associated with clinical failure included age >80 years in cohort 1 and ESRD across both cohorts. ESRD was associated with hemodynamic failure in cohort 1. Factors associated with slower resolution of presenting symptoms included diabetes in cohort 1 and WIfI stage in cohort 2. CONCLUSIONS: Durable clinical and hemodynamic benefit after revascularization for CLTI is important to avoid persistent and recurrent CLTI, reinterventions, and limb loss. When compared with ENDO, initial treatment with OPEN surgical bypass, particularly with available saphenous vein, is associated with improved clinical and hemodynamic outcomes and enhanced resolution of CLTI symptoms.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Menard MT, Farber A, Doros G, et al. The impact of revascularization strategy on clinical failure, hemodynamic failure, and chronic limb-threatening ischemia symptoms in the BEST-CLI Trial. J Vasc Surg. 2024. PMID: 39069016. doi:10.1016/j.jvs.2024.07.085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。